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Pheochromocytoma (PCC) and paraganglioma (PGL) are rare neuroendocrine tumors
associated with high cardiovascular morbidity and variable risk of malignancy. The current
therapy of choice is surgical resection. Nevertheless, PCCs/PGLs are associated with
a lifelong risk of tumor persistence or recurrence. A high rate of germline or somatic
mutations in numerous genes has been found in these tumors. For some, the tumorigenic
processes are initiated during embryogenesis. Such tumors carry genemutations leading
to pseudohypoxic phenotypes and show more immature characteristics than other
chromaffin cell tumors; they are also often multifocal or metastatic and occur at an
early age, often during childhood. Cancer stem cells (CSCs) are cells with an inherent
ability of self-renewal, de-differentiation, and capacity to initiate and maintain malignant
tumor growth. Targeting CSCs to inhibit cancer progression has become an attractive
anti-cancer therapeutic strategy. Despite progress for this strategy for solid tumors such
as neuroblastoma, brain, breast, and colon cancers, no substantial advance has been
made employing similar strategies in PCCs/PGLs. In the current review, we discuss
findings related to the identification of normal chromaffin stem cells and CSCs, pathways
involved in regulating the development of CSCs, and the importance of the stem cell
niche in development andmaintenance of CSCs in PCCs/PGLs. Additionally, we examine
the development and feasibility of novel CSC-targeted therapeutic strategies aimed at
eradicating especially recurrent and metastatic tumors.
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INTRODUCTION
The adrenal gland is composed of two main tissue types that establish a bidirectional connection;
the catecholamine-producing chromaffin cells in the medulla and the primarily steroid-producing
cells in the cortex. The inner medulla is derived from neuro-ectodermal cells of neural crest origin
while the outer cortex is derived from the intermediate mesoderm. Close interactions between the
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two components are necessary for differentiation
and morphogenesis of the gland (1, 2). Although
highly heterogeneous, pheochromocytomas (PCCs) and
paragangliomas (PGLs) are generally slow growing neural
crest-derived tumors comprised of chromaffin cells arising at
intra- and extra-adrenal locations, respectively (3). The tumors
show a very high rate of germline or somatic mutations in a
large number of genes (4, 5). When occurring at a young age,
the tumors are often multifocal, suggesting development during
embryogenesis from a common progenitor during neural crest
migration to different sites of tumorigenesis (6).
STEM CELLS IN THE NORMAL ADRENAL
MEDULLA
The neural crest represents a migratory population of
multipotent cells transiently present during embryogenesis,
which gives rise to a diverse variety of cell types and tissues
(7–9). At 11.5 days post coitum (dpc) in the mouse, early neural
crest cells migrate near the dorsal aorta, and form the suprarenal
ganglion. These progenitors will give rise to both chromaffin
cells and neurons, which innervate the adrenal medulla. From
11.5 to 15.5 dpc, late neural crest cells migrate toward the dorsal
root ganglion, where they acquire a Schwann cell precursor
(SCP) fate and express the transcription factor SOX10, which
is reported to be expressed in human, bovine and murine
chromaffin progenitors and stem cells (10–12). SOX10-positive
SCPs migrate along the nerves toward the medulla primordium,
and give rise to over 50% of the adrenomedullary chromaffin
cells (13). The majority of chromaffin cells of the Zuckerkandl
organ, which is the largest extra-adrenal chromaffin body in
mammals, are also generated from SCPs (14). Until recently, it
was believed that sympathoblasts and chromaffin cells originate
from a common progenitor (15), but the recent studies of SCPs
show an earlier segregation of the two lineages (14). SCPs have
lately attracted considerable attention due to numerous reports
highlighting their role as multipotent progenitors generating
various fates in the body (16–20). In addition to giving rise
to chromaffin and mature Schwann cells, SCPs propagate to
mesenchymal stem cells (21–23), endoneural fibroblasts (24),
and melanocytes (25), which use the peripheral nerves to reach
their specific locations in the developing embryo (18).
The postnatal adrenal medulla is composed of two main
differentiated cell types: catecholamine-producing chromaffin
cells, which represent the functional unit of the gland, and
neurons stimulating the catecholamine production. A third cell
type of the adrenal medulla has been identified as “sustentacular”
or “support” cells. These cells are of glial nature and express
S100B, GFAP, and Vimentin (26). Sustentacular cells are found
in proximity to both chromaffin cells and nerve terminations,
but their function has not been clarified yet. Sustentacular cell
markers are expressed by Nestin-positive cells, proposed to be
stress-responsive progenitors of the adrenal medulla (11). The
cytoskeletal type VI intermediate filament Nestin was initially
identified as a marker of neural stem and progenitor cells
(27, 28), but was later shown to be expressed in a variety of
tissues and other stem or progenitor cells (29). Nestin appears
to be linked to essential stem cell functions including self-
renewal/proliferation, differentiation and migration (29), and is
expressed in progenitors of both the adrenal cortex and medulla
(30, 31). Furthermore, Nestin seems to correlate with malignancy
in several different cancer types (32). In the adrenal medulla,
Nestin-positive cells overlap with CD133-positive cells and can
differentiate into chromaffin cells and cells of the neural lineages
(11). CD133 is expressed by progenitor/stem cells in several
organs including the brain under healthy or cancerous conditions
[for review see (33)], and expression of CD133 has also been
demonstrated in primary cultures of human and bovine adrenal
medullary cells grown under stem cell promoting conditions
(10, 12).
TUMORIGENESIS OF PCCS AND PGLS
Around 30–40% of PCCs/PGLs are hereditary due to mutations
in close to 20 currently identified PCC/PGL susceptibility genes,
whereas another 40–50% show somatic mutations in the same as
well as other genes (34, 35). At the time of PCC/PGL diagnosis,
the mean age of patients is 40–50 years, though 10–20% of all
cases are diagnosed in children (36). PCCs/PGLs can be divided
into two main clusters depending on their underlying mutations
in any of the susceptibility genes: the pseudohypoxia-associated
cluster 1 and the kinase signaling-associated cluster 2 (4, 34).
A third WNT signaling-associated cluster due to translocation
of MAML3 has also recently been described (35), but remains
poorly characterized. Genes most commonly contributing to
cluster 1 PCCs/PGLs are those encoding the four subunits of the
succinate dehydrogenase (SDH) enzyme, namely SDHA, SDHB,
SDHC, and SDHD, and the SDH assembly co-factor SDHAF2.
Other genes associated with a pseudohypoxic signature include
VHL, EPAS1, FH,MDH2, and EGLN1/2. Chromaffin cell tumors
arising due to mutations affecting SDH, but particularly SDHB,
are predominantly aggressive and often malignant. These tumors
and those due to VHL mutations often occur in childhood
suggesting development during embryogenesis from a common
stem cell/progenitor. According to the classical “two-hit” model,
two mutations are a prerequisite for tumorigenesis resulting
from loss of function mutations. In addition to the original
germline/somatic mutation, tumorigenesis requires a second
somatic mutation of the same gene (37). However, compared
to other tumors PCCs/PGLs exhibit a low somatic mutation
rate (35) suggesting that at least in pediatric tumors a single
mutation is sufficient for tumorigenesis. Cluster 2 tumors include
mutations in the RET, NF1, TMEM127, and MAX genes and are
characterized by activated PI3K/AKT/mTOR and RAS/RAF/ERK
downstream kinase and protein translation signaling pathways
(38). These tumors almost always originate in the adrenals, and
clinically they do not display a particularly aggressive behavior.
Furthermore, they have more mature catecholamine secretory
pathways and phenotypic features, and they tend to develop later
in life than tumors due to cluster 1 mutations (6, 39).
Normal stem cells are regulated by extrinsic cytokines as
well as by intrinsic genetic programs within their niche (40).
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This niche must be pliable to coordinate both homeostasis
and repair; however, such flexibility can be distorted by
chronic diseases and cancer. During embryonic development,
especially before vascularization, cells exist in a relatively
oxygen-poor environment. Consequently, oxygen sensing
pathways play crucial roles in ensuring appropriate embryonic
morphological development and survival (41). Similarly,
intratumoral hypoxia provides a microenvironment that shields
CSCs and stimulates their proliferation (42). Under changing
oxygen levels hypoxia-inducible transcription factors (HIFs)
activate genes that promote tolerance of hypoxia by decreasing
the cellular requirements for oxygen and by increasing the
supply of oxygen (43–45). This is potentially mediated by two
HIF isoforms, HIF1α and HIF2α differentially coordinating
migration, survival and differentiation of neural crest
cells (46, 47).
The common denominator for the pseudohypoxic phenotype
of all cluster 1 tumors involves HIF stabilization. It appears
that stabilization of HIF2α rather than HIF1α is responsible
for tumor development and the distinct phenotypic features of
cluster 1 chromaffin cell tumors (47). Stabilization of HIF2α
also provides the unifying mechanism responsible for the
pseudohypoxic phenotypes of all cluster 1 PCCs/PGLs (48).
Mutations in the EPAS1 gene encoding HIF2α are almost
always somatic, but still often involve a syndromic presentation
including polycythemia (elevated volume of red blood cells in
the blood) and somatostatinomas (49, 50). Although lacking
the central pseudohypoxic footprint, the cluster 2 tumors
relies on a glycolytic and glutaminolytic switch, necessary
for cell proliferation and survival, as well as for chromatin
remodeling. This means that even though genetically there is
a high heterogeneity in PCCs/PGLs, the molecular pathways
defining the three clusters are interrelated and all participate in
developmental processes (51).
Especially in cluster 1 tumors that develop early in life,
mutated SCPs might be one of the initiating tumorigenic cell
types since recent data on SCPs reveal that they can give rise
to both adrenal and extra-adrenal chromaffin cells. Furthermore,
PCCs and PGLs share diagnostic markers. Other tumor-initiating
cell types could be chromaffin cells, sympathetic-like chromaffin
cells or sympathoblasts (Figure 1).
Even if the chromaffin cells in the adrenal medulla and extra-
adrenal tissues, like the Zuckerkandl organ, have the same origin,
they are quite different at later developmental steps (14). This
suggests that the earlier the mutation happens, the higher the risk
for developingmultifocal tumors.When themutation arises later,
the progenitor cell is already committed to giving rise to either
intra- or extra-adrenal chromaffin tissue. This might also explain
the differences in metastatic potential between PCCs and PGLs
as about 10–20% of PCCs are metastatic, whereas up to 50% of
PGLs are metastatic (52).
The high prevalence of multifocal tumors at a young age
may indicate secondary somatic mutations before the settlement
of migrating SCPs at different locations. In support of this
concept, PGLs carrying somatic EPAS1 (HIF2α) mutations are
associated with mosaicism and identical mutations in multiple
tumor sites, consistent with the timing of tumor development
as a result of postzygotic mutations during early embryogenesis
(53, 54). During embryonic development, a large proportion of
sympatho-adrenal progenitors undergo programmed cell death.
This is also in keeping with observations that paraganglial
chromaffin tissue, and particularly the Zuckerkandl organ,
are well developed in the late-stage human fetus and regress
after birth with only vestigial clusters of cells persisting into
adulthood (55). These extra-adrenal clusters of chromaffin cells
may reflect the remnants of the hypoxia-sensing peripheral
catecholamine system, which is more important during fetal
development than in adulthood. This is different from the
neural crest-derived carotid body that remains important
throughout adulthood for oxygen sensing. In a physiological
state, the carotid body responds to chronic hypoxia with
hyperplasia and hypertrophy of its neural and vascular
FIGURE 1 | Proposed model for the development of PCCs/PGLs. Under normal conditions, neural crest cells (NCCs) differentiate into SCPs and finally chromaffin
cells (ChCs) (blue arrows). In PCCs/PGLs, developing at an early age, somatic mutations in SCPs give rise to CSCs from where tumors develop (red arrows). Somatic
mutations happening in ChCs also give rise to PCCs/PGLs via chromaffin cancer cells (ChCCs) but with a later appearance (green arrows).
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tissue components. In order to do this neural crest-derived
progenitors in the carotid body retaining mesoectodermal
differentiation potential are reactivated in a HIF-dependent
manner (56–58).
CANCER STEM CELL MARKERS FOUND
IN PCCS AND PGLS
CSCs are self-renewing and due to their stem-like properties
they may be more resistant to chemotherapy and radiation
(59). As these cells are potentially at the basis of tumor
formation and thereby a potential target for future therapies,
a lot of attention has been focused on their existence and
impact in several other cancers, especially in endocrine and
neural tissues. Even though many of the PCC/PGL mutations
are related to stem cell markers (51), there are few studies
focusing on CSCs in PCCs/PGLs. Increasing evidence suggests
that CSCs are reliant on low oxygen conditions, and therefore on
HIF1α and HIF2α to maintain their stem cell features (47, 60).
Recently, it was shown that only in CSCs the pluripotency-
promoting transcription factors NANOG and SOX2 cooperate
with MYC to regulate HIF2α, which leads to a decrease in P53
expression and reduces the levels of reactive oxygen species
in CSCs thereby promoting stemness (61). This is supported
by other studies showing that primarily HIF2α is activated in
CSCs (62).
Often the results on the expression of stem cell markers
in PCCs/PGLs are contradictory, likely reflecting tumor
heterogeneity (Table 1). Though the molecular pathways in the
different tumors might be related, the amount of the different
cell types in the tumors and their levels of differentiation, remain
variable, possibly due to their microenvironment (51). For
example, the expression of OCT4 is inconsistent as a study by
Looijenga et al. concluded that PCCs/PGLs are negative for
OCT4 (63), yet a subsequent study by Alexander et al. showed
strong and diffuse cytoplasmic staining of OCT4 in PCCs and
metastases (64). Oudijk et al. analyzed the expression of relevant
CSC markers in tissue microarrays of a large number of PCCs
and PGLs and showed that frequently CSC marker expression
was associated with cluster 1 SDHx-mutated tumors (65),
though expression of CSC markers has also been observed in
PGLs from patients without SDHx mutations (66). Contrary to
the findings within other adrenal tumors, OCT4, CD133, and
NANOG expression was not detected in any of the samples from
Oudjik et al., however expression of other stem cell markers
such as DLK1/PREF1, NGFR, LIN28, SOX2, and THY1 was
observed in 12-40% of cases, whereas the expression of Nestin,
SOX17 and CD117 was identified less frequently in 2–3% of
cases (65). In contrast, a case study of a PCC in pregnancy
showed high expression of Nestin (67), which, as CD133, has
also been detected in PGLs (66). As Nestin marks sustentacular
cells, it raises questions regarding their role in PCCs/PGLs. To
TABLE 1 | CSC markers in PCCs/PGLs.
Marker Subcellular location Function Expression in PCCs/PGLs
(percentage of positive tumors)
References
OCT4 Nucleus and cytoplasm Transcription factor
Important for maintaining pluripotency, forms a complex with
SOX2, regulates NANOG
+(0–100%) (63–65)
NANOG Nucleus Transcription factor
Important for maintaining pluripotency
– (65)
SOX2 Nucleus Transcription factor
Expressed in the developing CNS Important for maintaining
pluripotency, forms a complex with OCT4
+(12%) (65)
SOX17 Nucleus Transcription factor
Regulates embryonic development
+(2%) (65)
Nestin Cytoplasm Type VI intermediate filament
Marker of neural stem/progenitor cells
+(3%) (65–67)
CD90 (THY1) Cell membrane N-glycosylated, glycophosphatidylinositol anchored cell
surface protein
Marker of various stem cells
+(40%) (65, 66)
CD117 (C-kit) Cell membrane Tyrosine-protein kinase acting as a receptor for c-kit ligand.
Involved in growth and development of the cerebral cortex
+(3–14%) (65, 66, 68, 69)
CD133 (Prominin-1) Cell membrane Cell surface glycoprotein
Plays a role in cell differentiation, proliferation and apoptosis
± (65, 66)
CD271 (NGFR) Cell membrane Nerve growth factor receptor




RNA binding protein enhancing translation of IGF-2
Regulates self-renewal of stem cells
+(24%) (65)
DLK1 (PREF1) Cell membrane Protein Delta Homolog 1, transmembrane protein belonging
to the EGF-like homeotic protein family
Plays a critical role in differentiation processes
+(19%) (65, 66)
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date, the precise role of this cell type in the normal adrenal
medulla and in PCCs/PGLs has not been clarified. Several
studies demonstrated differences in the number of sustentacular
cells in primary and metastatic PCCs (70, 71), and a case
of a distinctive neoplasm thought to have originated from
S100-positive sustentacular cells has previously been reported
(72). These observations support the notion that sustentacular
cells may have a role in tumor formation or metastasis of
PCCs/PGLs. However, these results also show the paucity of
studies analyzing the expression of CSC markers in all clusters
of PCCs/PGLs.
CSC TARGETED THERAPIES
When possible, surgery is always the therapy of choice
for non-metastatic PCC/PGL. With metastatic disease,
a primary tumor resection is recommended followed
by radiotherapy or classical chemotherapy [reviewed in
(73)]. In the case of progression or if classical therapies
are not possible or tolerated by the patient, targeted
therapies might be considered. As most PCCs/PGLs show
a high expression of somatostatin receptor subtype 2,
radiolabeled somatostatin analogs have been investigated
as a treatment option (74). Other targeted therapies with
for example different tyrosine receptor kinase inhibitors
are under investigation and show promising results (73).
As PCCs/PGLs occasionally express CD117 (Table 1), the
tyrosine kinase inhibitor imatinib has for example been
tested on in vitro cultures of PGL cell cultures, where it
was shown to inhibit growth of both SDHx-unrelated and
related tumor cells. Furthermore, it prevented xenograft
formation in mice transplanted with patient-derived
cells (66).
CSCs are known to be more resistant to conventional
chemo- and radio-therapy compared to non-CSC populations.
Pre-clinical and clinical trials in multiple tumor types have
targeted CSCs via surface markers, inhibition of developmental
stem cell pathways, or ablation of CSC niches [reviewed in
(75)]. In neuroblastoma (NB) a common link between signaling
cascades involved in tumorigenesis is hypoxia, and in hypoxic
regions of NB, HIF1, and HIF2 have been shown to be
expressed in cells with stem-like features (76). NB is the most
common extracranial pediatric solid tumor, which often arises
in infants and children up to 5 years (77). It originates from
embryonic neural crest cells during early embryogenesis and
mutated SCPs are likely also in these tumors the initiator cells
(14). In contrast to PCCs/PGLs, the expression of stem cell
markers in NB have been more studied (78). The existence of
CSCs in NB has been associated with malignancy, resistance
to chemotherapy and recurrence (79), as in chemo- and/or
radiation-resistant NB cancer stem-like cells an increased
expression of the stem cell markers CD133, SOX2, ALDH1,
Nestin, OCT4, and NANOG was observed (80). Additionally,
populations of cells positive for Nestin, CXCR4, and OCT4
were increased in late-stage NB (81). It has been suggested that
differentiation of such NB CSCs may render them more sensitive
to therapeutic intervention (78). One way to induce cancer
differentiation in NB is to use retinoic acid (82), and actually
combined retinoic acid treatment and proteasome inhibition
demonstrated the ability to inhibit tumor-sphere formation
and apoptosis in NB CSCs. Also the expression of Nestin,
SOX2, and OCT4 was reduced with this treatment (83). Other
combination therapies for NB CSCs showed promising results
as well [reviewed in (78)]. Because of the similarity in origin
and CSC marker expression between NB and PCCs/PGLs,
these therapies might also be an option for the treatment
of PCCs/PGLs.
In glioblastoma, the epidermal growth factor receptor (EGFR)
antagonist nimotuzumab targeting CD133 has been shown to
radiosensitize subpopulations of cells (84). Furthermore, anti-
EGFR therapy in combination with conventional therapy has
shown promising results in patients with epithelial cancers
(85–87). Furthermore, in a cohort of advanced basal cell
carcinoma patients, Von Hoff et al. demonstrated a favorable
response to treatment with a small-molecule inhibitor of the
hedgehog pathway (88). Other studies have investigated the
NOTCH and WNT signaling pathways in multiple solid tumor
patient populations (89). Stem cell specific niche constituents
and their cognate receptors such as fibronectin and the
fibronectin receptor in acute myeloid leukemia and breast cancer,
respectively, have also been targeted and demonstrated strong
anti-tumorigenic activity (90, 91). Since many of these targets,
as e.g., NOTCH1 and CD133, are also expressed in metastatic
PCCs/PGLs (66), the CSC-targeted therapies mentioned above
might also be an opportunity for the treatment of these
tumor types.
CONCLUSION
While the existence of CSCs has been observed not only in
PCCs/PGLs but also in several other endocrine and neural tumor
types, the precise role of these cell types in tumor formation
and homeostasis remains largely unknown. PCCs/PGLs include
a subset of tumors in a pseudohypoxic state. The signaling
and tissue microenvironments described in this state seem
to encourage cell proliferation and survival and may even
support persistence of cells expressing embryonic stem cell
markers. Expression of several stem cell markers appears to
be associated with PCC/PGL mutations, although the precise
nature of this possible relationship needs to be further elucidated.
Additionally, sustentacular cells may play a role in tumor
development or invasiveness. However, there is still a need for
thorough characterization of these cells in tumor formation.
Finally, investigations into the homeostatic role of adult stem
cells within the normal adrenal medulla in comparison to
the tumor state may help understand the contribution of
CSCs to PCCs/PGLs, which might lead to new therapies
targeting CSCs in recurrent and metastatic PCCs/PGLs. Until
now, CSC targeted therapies have not been employed for the
treatment of PCCs/PGLs. However, due to similarity in the
expression of CSC markers known from other tumor types,
where CSC targeted therapies have shown promising results,
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these therapies might be an option for PCCs/PGLs as well. In
conclusion, characterization of CSCs in PCCs/PGLs and the
regimen of CSC targeted therapies of these tumors require
further research.
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